Chronic obesity does not alter cancer survival inTp53R270H/+mice DOI Creative Commons
Ilaria Panzeri, Zachary Madaj, Luca Fagnocchi

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 16, 2024

Abstract Obesity is a complex chronic disease characterized by excessive adiposity and associations with numerous co-morbidities, including cancer. Despite extensive research, we have limited understanding of the mechanisms coupling obesity to cancer risk, and, contexts in which does or not exacerbate disease. Here, show that high-fat diet (HFD)-induced has no significant effect on Tp53 R270H/+ mouse, model human Li-Fraumeni multi-cancer syndrome. Surprisingly, despite inducing rapid highly penetrant long-term differences metabolic adiposity, greater than one year HFD had survival tumor burden. These findings were replicated two separate cohorts thus provide important negative data for field. Given strong publication bias against literature, this large cohort study represents clear case where diet-induced accelerate aggravate outcomes. The carry high impact researchers, funders, policymakers alike.

Language: Английский

An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes DOI Creative Commons
Matthias Blüher

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Abstract Obesity is a highly prevalent chronic multisystem disease associated with shortened life expectancy due to number of adverse health outcomes. Epidemiological data link body weight and parameters central fat distribution an increasing risk for type 2 diabetes, hypertension, fatty liver diseases, cardiovascular diseases including myocardial infarction, heart failure, atrial fibrillation, stroke, obstructive sleep apnoea, osteoarthritis, mental disorders some types cancer. However, the individual develop cardiometabolic other obesity‐related cannot entirely be explained by increased mass. Rather than excess accumulation, dysfunction adipose tissue may represent mechanistic between obesity There are people living who seem protected against premature development diseases. On hand, normal typical upon predominantly visceral distribution. The mechanisms linking impaired function in include adipocyte hypertrophy, altered cellular composition, limited expandability safe subcutaneous stores, ectopic deposition depots, organs, hypoxia, variety stresses, inflammatory processes, release pro‐inflammatory, diabetogenic atherogenic signals. Genetic environmental factors might contribute either alone or via interaction intrinsic biological variation function. still many open questions regarding how causes whether these pathologies could reversed. Evidence‐based loss interventions using behaviour change, pharmacological surgical approaches have clarified beneficial effects realistic sustained on complications as hard This review focusses recent advances understanding epidemiological trends Plain Language Summary complex progressive characterized excessive that impair quality life. Worldwide, adults has more doubled since 1990. lead reduced expectancy, because it increases (e.g., high blood pressure, stroke), musculoskeletal respiratory depression certain not every person develops For better prevention treatment, important understand mass related It become clear explain higher complications. People can low developing Compared those abdominal region, average bigger cells, immune cells signals released from directly affect brain, liver, vasculature organs. Both inherited environment cause abnormalities through changes lower calorie intake, physical activity), medications surgery improve health, reduce

Language: Английский

Citations

2
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium DOI

Taizo Uchimoto,

Kengo Iwatsuki,

Kazumasa Komura

et al.

International Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Language: Английский

Citations

0
Risk factors for postoperative acute kidney injury after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: a meta-analysis and systematic review DOI Creative Commons

Dengzhuo Chen,

Yongli Ma, Jinghui Li

et al.

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 4, 2025

Acute kidney injury after CRS + HIPEC is a serious postoperative complication, but only few studies have reported its risk factors. In addition, there are large discrepancies in the results of available observational studies. We searched The Cochrane Library, Embase, Web Science,and PubMed to identify reporting factors for AKI HIPEC. A meta-analysis was performed investigate effect various preoperative and intraoperative on total 7 were included this study, comprising 1550 patients who developed showed that significant age, sex, BMI, eGFR, Hb, PCI, diabetes mellitus, hypertension. IO cisplatin, SBP < 100 identified as an factor, whereas mitomycin emerged protective factor AKI. varied by primary tumor site, with Appendix being less prone AKI, while mesothelioma ovarian, two sites greatly elevated This number By identifying these factors, it more beneficial clinicians perform early interventions select most appropriate treatment strategy their patients, thus minimizing PROSPERO CRD42024585269.

Language: Английский

Citations

0
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes DOI
Thomas Först, Christophe De Block, Stefano Del Prato

et al.

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 11, 2025

Abstract Obesity and type 2 diabetes mellitus (T2D) are widespread diseases that significantly impact cardiovascular renal morbidity mortality. In the recent years, intensive research has been performed to assess role of adipose tissue body fat distribution in development metabolic non‐metabolic complications individuals with obesity. addition lifestyle modifications, glucagon‐like peptide‐1 receptor agonists (GLP‐1‐RA) have become a meaningful treatment expansion for management both disorders. improving control reducing weight, GLP‐1‐RAs reduces events obesity without diabetes. These important benefits triggered new interest other enteroendocrine enteropancreatic peptides treating its consequences. The first peptide dual‐agonist targeting glucose‐dependent insulinotropic polypeptide (GIP) GLP‐1 receptors approved T2D GIP/GLP‐1 dual‐agonism appear provide better greater weight reduction compared GLP‐1‐R mono‐agonism. Other non‐peptide co‐agonists clinical obesity, T2D, dysfunction‐associated steatotic liver disease (MASLD) This narrative review aims summarize available data on emerging based approaches efficacy measures, side effects, limitations open challenges will also be addressed.

Language: Английский

Citations

0
Understanding the Role of Adipokines in Cardiometabolic Dysfunction: A Review of Current Knowledge DOI Creative Commons
Sayantap Datta, Saisudha Koka, Krishna M. Boini

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(5), P. 612 - 612

Published: April 23, 2025

Cardiometabolic risk and associated dysfunctions contribute largely to the recent rise in mortality globally. Advancements multi-omics years promise a better understanding of potential biomarkers that enable an early diagnosis cardiometabolic dysfunction. However, molecular mechanisms driving onset progression disorders remain poorly understood. Adipokines are adipocyte-specific cytokines central deleterious alterations. They exhibit both pro-inflammatory anti-inflammatory effects, complicating their association with disturbances. Thus, adipokines from signaling perspective assumes great importance. This review presents comprehensive outline most prominent exhibiting and/or functions The also insight into pathophysiological implications such different dysfunction conditions, status adipokine druggability, future studies can be undertaken address existing scientific gap. A clear functional mechanistic role potentially improve our cardiovascular disease pathophysiology enhance current therapeutic regimen come.

Language: Английский

Citations

0
Chronic obesity does not alter cancer survival inTp53R270H/+mice DOI Creative Commons
Ilaria Panzeri, Zachary Madaj, Luca Fagnocchi

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 16, 2024

Abstract Obesity is a complex chronic disease characterized by excessive adiposity and associations with numerous co-morbidities, including cancer. Despite extensive research, we have limited understanding of the mechanisms coupling obesity to cancer risk, and, contexts in which does or not exacerbate disease. Here, show that high-fat diet (HFD)-induced has no significant effect on Tp53 R270H/+ mouse, model human Li-Fraumeni multi-cancer syndrome. Surprisingly, despite inducing rapid highly penetrant long-term differences metabolic adiposity, greater than one year HFD had survival tumor burden. These findings were replicated two separate cohorts thus provide important negative data for field. Given strong publication bias against literature, this large cohort study represents clear case where diet-induced accelerate aggravate outcomes. The carry high impact researchers, funders, policymakers alike.

Language: Английский

Citations

0